ArticleScientific reports2025
Synthesis of silver nanoparticles from Vicia faba aqueous extract with cytotoxic activity against human acute T cell leukemia.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Silver Nanoparticles as Anticancer Agents: Mechanisms Insight, Current Studies, and Limitations.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Facile and efficient synthesis of silver nanoparticles using Stachys viscosa with phenolic profiling, antioxidant potential and cytotoxic activity.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Silver nanoparticles (AgNPs) are among the most extensively utilized nanomaterials in commercial and biomedical applications due to their potent cytotoxic properties. Leukemia remains one of the most prevalent cancers worldwide, driving the search for novel therapeutic approaches. In this study, aqueous extracts from Vicia faba seed coats were employed for the green synthesis of AgNPs, and their anticancer activity was evaluated in vitro. The biosynthesized AgNPs exhibited an average hydrodynamic diameter of 23.14 ± 0.20 nm, with all particles measuring under 40 nm, and showed a characteristic surface plasmon resonance (SPR) peak at 430 nm. X-ray diffraction (XRD) analysis confirmed the crystalline nature of the nanoparticles, revealing distinct peaks corresponding to the (111), (200), (220), and (311) planes of metallic silver. Fourier-transform infrared spectroscopy (FTIR) indicated the presence of phenolic functional groups from the extract, likely involved in nanoparticle formation and stabilization. Cell viability assays demonstrated a dose-dependent cytotoxic effect on leukemia cells, with an IC₅₀ of 2.27 mg/mL. Apoptosis induction was confirmed by flow cytometry using the Annexin V assay, which revealed a significant increase in apoptotic cell populations with increasing AgNPs concentrations. Additionally, an increased percentage of cells in the sub-G1 phase was observed, further supporting apoptotic activity. At a concentration of 3 mg/mL, the AgNPs significantly reduced cell viability. These findings suggest that the proposed one-step, cost-effective biosynthesis method yields AgNPs with promising anticancer properties, highlighting their potential as a therapeutic tool for leukemia treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.